KLRA Kailera Therapeutics, Inc.
Price Chart
Executive Summary
Kailera Therapeutics and Hengrui Pharma presented positive Phase 2 oral and Phase 1 injection data for ribupatide (GLP-1/GIP dual agonist) at ADA 2026. The oral achieved up to 12.1% mean weight loss at 26 weeks with a favorable GI tolerability profile, and the injection showed similar exposure/weight reduction across Asian and non-Asian populations. The data supports advancing to Phase 3 globally, with oral Phase 3 expected to start in H1 2027.
Actionable Insight
The compelling efficacy and tolerability profile of ribupatide oral strengthens Kailera's position in the obesity space. Monitor for FDA feedback on Phase 3 oral trial design and initiation timeline in H1 2027. The injection Phase 3 (KaiNETIC) is already ongoing — positive data readouts would be the next major catalyst.
Key Facts
- Phase 2 oral ribupatide met primary endpoint: mean weight loss up to 12.1% (25mg/50mg) vs 2.3% placebo at Week 26, with no plateau observed.
- 38.6% of participants on 25mg oral achieved ≥15% weight loss; GI adverse events were low (vomiting 11.4% at 25mg, 7.5% at 50mg).
- Phase 1 injection bridging study showed similar exposure and weight reduction in Asian and non-Asian participants, supporting global Phase 3 KaiNETIC program.
- Kailera plans to initiate global Phase 3 trials for ribupatide oral as early as H1 2027, subject to FDA discussions.
- Hengrui has submitted an NDA in China for ribupatide injection for long-term weight management.
Financial Impact
No financial figures provided; clinical data supports advancement of a potentially best-in-class oral GLP-1/GIP dual agonist in a $100B+ obesity market.
Risk Factors
- Phase 3 oral trials may fail to replicate Phase 2 results or face regulatory delays.
- Competition from other oral GLP-1/GIP agonists (e.g., Eli Lilly's orforglipron) could erode market share.
- Manufacturing scale-up and oral bioavailability challenges could impact commercial viability.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
15d ago
|
Press Release
| $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $19.90 (+1.02%) |
|
May 26, 2026
25d ago
|
8-K
| $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $19.90 (−9.17%) |
|
May 26, 2026
25d ago
|
Press Release
| $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $19.90 (−9.17%) |
|
May 13, 2026
5w ago
|
Press Release
| $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $19.90 (−5.73%) |
|
Apr 20, 2026
8w ago
|
8-K
| $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $19.90 (−21.09%) |
|
Apr 20, 2026
8w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.90 (−19.14%) |
|
Apr 20, 2026
8w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.90 (−19.14%) |
|
Apr 20, 2026
8w ago
|
Insider Cluster
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.90 (−19.14%) |
|
Apr 17, 2026
9w ago
|
424B4
| $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $19.90 (−19.14%) |
|
Apr 17, 2026
9w ago
|
EFFECT
| $26.00 $22.47 | ▼ −13.58% | ▼ −14.13% | $19.90 (−23.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access